

Clustering of iron oxide nanoparticles into poly(ethylene oxide)-*block*-poly(ϵ -caprolactone) nanoassemblies as ultrasensitive MRI probes

A. Hannecart¹, D. Stanicki¹, L. Vander Elst^{1, 2}, L. Mespouille³, R. N. Muller^{1, 2}, S. Laurent^{1, 2}

¹NMR and Molecular Imaging Laboratory, General, Organic and Biomedical Chemistry Department, University of Mons, B-7000 Mons, Belgium

²Center for Microscopy and Molecular Imaging, B-6041 Charleroi, Belgium

³Laboratory of Polymeric and Composite Materials, University of Mons, B-7000 Mons, Belgium

Introduction

Polymer vesicles, called polymersomes, are hollow spheres formed by the self-assembly of amphiphilic polymers with long hydrophobic blocks (Fig 1.). Thanks to their high robustness, polymersomes have emerged as promising nanocarriers. The objective of this project is to study the self-assembly of PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ copolymers with ultrasensitive iron oxide nanoparticles (USPIO). A composition close to PEO₂₀₀₀-*b*-PCL₁₂₀₀₀ was chosen owing to the tendency of these copolymers to form a vesicular morphology. Several studies have reported the formation of poly(ethylene oxide)-*block*-poly(ϵ -caprolactone) (PEO-*b*-PCL) based vesicles due to their high potential for biomedical applications. However, to the best of our knowledge, no work has been done on the incorporation of USPIO into nanoassemblies produced from PEO-*b*-PCL copolymers with long PCL blocks.




Figure 1. Schematic representation of a polymersome

Material and methods




Figure 2. Self-assembly of PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ with USPIO by the nanoprecipitation method

USPIO (magnetic core size of 4.2 nm and 7.5 nm) were produced by thermal decomposition of iron(III) acetylacetonate in the presence of surfactants in an organic solvent at high temperature (>200°C).

Nanoprecipitation of PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ with iron oxide nanoparticles was performed by varying the initial nanoparticle concentration (Fig. 2). The best results were obtained by mixing 10 mg of copolymer with 500 μ l of THF containing USPIO ([Fe]₀ = 40 mM for d_{USPIO} = 7.5 nm, [Fe]₀ = 80 mM for d_{USPIO} = 4.2 nm).

Results and discussions

Size and morphology

Dynamic light scattering (DLS), transmission electron microscopy (TEM) and cryo-TEM analyses (Fig. 3) showed that nano-objets produced by the self-assembly of PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ with USPIO are spherical, possess a high USPIO content and a diameter close to 100 nm




Figure 3. Cryo-TEM images* of PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ nanoassemblies loaded with USPIO (d_{USPIO} = 7.5 nm)

r₁ and r₂ relaxivities

The efficiency of a MRI (magnetic resonance imaging) contrast agent is quantified by its longitudinal and transverse relaxivities (r₁ and r₂). T₂-weighted contrast agents decrease MRI signal intensity where they accumulate. The most effective T₂-weighted contrast agents are those characterized by the higher r₂/r₁ ratio. Incorporation of USPIO into PEO-*b*-PCL nanoparticles leads to a significant increase of r₂/r₁ ratios (r₁ decreases due to a reduced accessibility of water protons to USPIO and r₂ increases due to USPIO clustering) (table 1).

Table 1. Relaxivities (r₁ and r₂) at 37°C and 60 MHz

	r ₁ (s ⁻¹ mM ⁻¹)	r ₂ (s ⁻¹ mM ⁻¹)	r ₂ /r ₁	r ₁ (s ⁻¹ mM ⁻¹)	r ₂ (s ⁻¹ mM ⁻¹)	r ₂ /r ₁
	USPIO (THF)			USPIO loaded in PEO ₂₀₀₀ - <i>b</i> -PCL ₁₂₆₅₀ (water)		
d _{USPIO} = 7.5 nm	12.9	37.8	3.0	1.22	198	162
d _{USPIO} = 4.2 nm	7.8	17.9	2.3	0.28	110	389

Conclusions and perspectives

USPIO possessing two different diameters (d = 4.2 nm and d = 7.5 nm) were produced by the thermal decomposition method and incorporated into PEO₂₀₀₀-*b*-PCL₁₂₆₅₀ nanoassemblies by a nanoprecipitation method. Extrusions were performed to produce 100 nm diameter polymeric nanoparticles with a narrow size distribution which is ideal for *in vivo* applications. These polymeric nanoparticles were loaded with a high USPIO content by optimizing the initial USPIO concentration and are characterized by very high r₂/r₁ ratios which demonstrates that they are promising candidates as T₂-contrast agents. Further research will focus on the incorporation of an anti-cancer drug into these nanocarriers and the attachment of an active targeting group such as an RGD-containing peptide to their surfaces.

